Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2023-11-23 Management Reports
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane Biopharma fokuserar utvecklingsportföljen och inför ett kostnadsbesparingsprogram
Management Reports Classification · 99% confidence The document is a press release from Xbrane Biopharma AB announcing strategic changes, including focusing the development portfolio and implementing a cost-saving program resulting in annual savings of approximately 50 million SEK and staff reductions. It mentions achieving positive cash flow and provides contact information and an 'About Us' section. Crucially, at the end, it states: "Denna information är sådan information som Xbrane Biopharma är skyldigt att offentliggöra enligt EU: s marknadsmissbruksförordning" (This information is information that Xbrane Biopharma is obliged to disclose pursuant to the EU's Market Abuse Regulation) and includes a link to a PDF attachment. This structure—a brief announcement of material corporate news that is legally required to be disclosed, often referencing regulatory obligations (like MAR)—is characteristic of a general regulatory announcement, which falls under the 'Regulatory Filings' (RNS) category, especially since it is not a specific financial report (10-K, IR, ER) or a specific corporate action announcement (DIV, CAP, SHA). Given the short length (under 5,000 characters) and the nature of announcing the publication of information, RNS is the most appropriate general regulatory classification.
2023-11-23 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by Avanza Bank Holding AB for its subsidiary, specifically noting a resulting holding of 4.93064% and a total holding including instruments of 5.23181%. The structure, use of tables detailing shares, voting rights, and notes referencing legal articles (LHF 4 kap, 2§) strongly indicates a formal notification regarding significant ownership changes. This aligns precisely with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-11-20 English
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a change in the total number of shares and votes due to the exercise of warrants under an LTIP. This directly relates to a change in the company's capital structure or share count. The filing category 'Share Issue/Capital Change' (SHA) is the most appropriate fit for reporting changes in the number of outstanding shares. Although it mentions being obliged to make public pursuant to the Financial Instruments Trading Act, the core content is a share count update, not a general regulatory filing (RNS) or a dividend announcement (DIV). It is not a proxy statement (PSI) or a director's dealing (DIRS).
2023-10-31 English
Xbrane Biopharma AB ("Xbrane" eller "Bolaget") meddelar om förändring av antalet aktier och röster i Bolaget.
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a change in the total number of shares and votes due to the issuance of new shares following the exercise of stock options (LTIP 2020). This directly relates to a change in the company's capital structure, specifically the number of outstanding shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core subject is the capital change itself, not just the announcement of a report, making SHA a better fit than RPA or RNS. The document states the new total number of shares as of October 31, 2023.
2023-10-31 Swedish
Xbrane Biopharma presenterar Valberedning
Board/Management Information Classification · 99% confidence The document is a short announcement in Swedish titled "Xbrane Biopharma presenterar Valberedning" (Xbrane Biopharma presents Nomination Committee). It details the composition of the Nomination Committee for the upcoming 2024 Annual General Meeting (AGM), naming the representatives from major shareholders and outlining the committee's tasks (proposing board members, remuneration, auditor, etc.). It also mentions the date of the AGM (May 2, 2024) and provides a deadline for shareholder proposals to the committee. Since this document is an announcement about the composition of a body related to the AGM and governance, and it is very short (3192 chars) and mentions that proposals will be presented in the AGM notice and on the website, it strongly relates to the governance and shareholder meeting process. The most fitting category is related to governance or AGM preparation. Given the focus on the Nomination Committee (Valberedning), which prepares proposals for the AGM, it aligns closely with Governance Information (CGR) or potentially AGM Information (AGM-R). However, since it is specifically about the *composition* and *mandate* of the committee preparing for the AGM, CGR (Governance Information) is a strong fit, as is AGM-R (AGM Information). Since the text explicitly details the structure and purpose of the committee responsible for nominating directors and setting remuneration for the AGM, it falls under corporate governance practices. I will classify it as Governance Information (CGR) as it details internal rules/structure related to board appointments, although AGM-R is also plausible. Given the context of shareholder meetings, AGM-R is often used for materials directly related to the meeting itself or its preparatory bodies. Let's re-evaluate: The document is about the Nomination Committee, which is a key governance body preparing for the AGM. CGR covers 'internal rules, board structure, and governance practices'. AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. This is a pre-AGM announcement about a preparatory body. CGR seems slightly more precise for the structure of the committee itself. However, if we consider the context of shareholder interaction, it is highly related to the AGM. Given the options, and the focus on the committee that sets the stage for the AGM, CGR is appropriate for governance structure, but AGM-R covers the preparatory materials for the meeting. Since the text is an official announcement regarding the committee that handles board nominations for the AGM, I will select AGM-R as it is directly tied to the AGM process.
2023-10-18 Swedish
Xbrane Biopharma presents Nomination Committee
Board/Management Information Classification · 99% confidence The document explicitly discusses the composition and tasks of the Nomination Committee for the upcoming Annual General Meeting (AGM) in 2024. It details the appointment process based on shareholder voting power as of September 30, 2023, and outlines the committee's responsibilities regarding board proposals, fees, and auditor elections for the AGM. This content is directly related to the governance and preparation for the AGM. While it is an announcement, the core subject matter is the structure governing the AGM nominations, which aligns closely with governance/AGM materials. Since it is an announcement about the committee structure leading up to the AGM, and not the final voting results (DVA) or the full proxy statement (PSI), it fits best under the general umbrella of AGM-related information or Governance Information (CGR). Given the specific focus on the Nomination Committee's setup for the AGM, AGM-R is the most precise fit, as the committee's work directly feeds into the AGM agenda.
2023-10-18 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.